Contrasting Nutra Pharma (OTCMKTS:NPHC) and Seer (NASDAQ:SEER)

Seer (NASDAQ:SEER) and Nutra Pharma (OTCMKTS:NPHC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Insider and Institutional Ownership

75.2% of Seer shares are owned by institutional investors. 11.3% of Seer shares are owned by insiders. Comparatively, 61.5% of Nutra Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Seer and Nutra Pharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seer	1	0	1	1	2.67
Nutra Pharma	0	0	0	0	0.00

Seer currently has a consensus price target of $4.00, suggesting a potential upside of 105.13%. Given Seer’s stronger consensus rating and higher probable upside, research analysts plainly believe Seer is more favorable than Nutra Pharma.

Valuation and Earnings

This table compares Seer and Nutra Pharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seer	$16.58 million	6.64	-$73.60 million	($1.28)	-1.52
Nutra Pharma	$390,000.00	5.51	-$1.29 million	N/A	N/A

Nutra Pharma has lower revenue, but higher earnings than Seer.

Profitability

This table compares Seer and Nutra Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Seer	-443.96%	-26.04%	-23.10%
Nutra Pharma	-429.26%	N/A	-106.42%

Risk & Volatility

Seer has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. Comparatively, Nutra Pharma has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500.

Summary

Seer beats Nutra Pharma on 9 of the 13 factors compared between the two stocks.

About Seer

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

About Nutra Pharma

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, nonnarcotic, nonaddictive, and overthecounter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and antiinflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.